Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SLC13A5 | Q86YT5 | 12/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.38 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554363 | 1.00 | ALDH1A1 (0.52) | ALDH1A1SLC13A5ALOX15SLC13A2SLC13A3 | |
| SCHEMBL1734711 | 0.82 | ALOX15 (0.37) | ALDH1A1SLC13A5ALOX15SLC13A2SLC13A3 | |
| Citric Acid SCHEMBL19212595 | 0.82 | ALOX15 (0.67) | ALDH1A1SLC13A5ALOX15SLC13A2SLC13A3 | |
| SCHEMBL14633990 | 0.80 | ALDH1A1 (0.56) | ALDH1A1SLC13A5ALOX15KDM4EATM | |
| SCHEMBL6436094 | 0.78 | HMGCR (0.54) | ALDH1A1ALOX15KDM4EATMHMGCR | |
| Citric Acid SCHEMBL20481370 | 0.76 | KMT2A (0.59) | ALDH1A1ALOX15KDM4EATMFNTA | |
| SCHEMBL4748771 | 0.75 | ALOX15 (0.52) | ALDH1A1ALOX15KDM4EATMTSHR | |
| Citric Acid SCHEMBL8107350 | 0.74 | ALDH1A1 (0.83) | ALDH1A1SLC13A5ALOX15KDM4EHMGCR | |
| Citric Acid SCHEMBL1735796 | 0.74 | ALDH1A1 (0.83) | ALDH1A1SLC13A5ALOX15KDM4EHMGCR | |
| Citric Acid SCHEMBL10934305 | 0.74 | ALDH1A1 (0.83) | ALDH1A1SLC13A5ALOX15KDM4EHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907371-A1 | PROCESS FOR PREPARING 2-METHOXYCARBONYLMETHYL-6,6-DIMETHYL-2- TETRAHYDROPYRAN CARBOXYLIC ACID | ERREGIERRE S.p.A. (IT) | 2008-04-09 | — | — | EP | claimed |
| WO-2007009953-A1 | PROCESS FOR PREPARING 2-METHOXYCARBONYLMETHYL-6,6-DIMETHYL-2- TETRAHYDROPYRAN CARBOXYLIC ACID | ERREGIERRE S.P.A. (IT) | 2007-01-25 | — | — | WO | claimed |
| WO-2018019549-A1 | DIOXOLANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF HOMOHARRINGTONINE | INDENA S.P.A. (IT) | 2018-02-01 | — | — | WO | disclosed |
| EP-3275875-A1 | DIOXOLANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF HOMOHARRINGTONINE | INDENA S.p.A. (IT) | 2018-01-31 | — | — | EP | disclosed |
| US-RE45128-E1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2014-09-09 | — | — | US | disclosed |
| US-RE45128-E1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2014-09-09 | — | — | US | disclosed |
| EP-1907371-B1 | PROCESS FOR PREPARING 2-METHOXYCARBONYLMETHYL-6,6-DIMETHYL-2- TETRAHYDROPYRAN CARBOXYLIC ACID | ERREGIERRE SPA (IT) | 2011-11-23 | — | — | EP | disclosed |
| EP-1907371-B1 | PROCESS FOR PREPARING 2-METHOXYCARBONYLMETHYL-6,6-DIMETHYL-2- TETRAHYDROPYRAN CARBOXYLIC ACID | ERREGIERRE SPA (IT) | 2011-11-23 | — | — | EP | disclosed |
| EP-1907371-B1 | PROCESS FOR PREPARING 2-METHOXYCARBONYLMETHYL-6,6-DIMETHYL-2- TETRAHYDROPYRAN CARBOXYLIC ACID | ERREGIERRE SPA (IT) | 2011-11-23 | — | — | EP | disclosed |
| US-8008514-B2 | Process for preparing 2-methoxycarbonylmethyl-6,6-dimethyl-2-tetrahydropyran carboxylic acid | ERREGIERRE S.P.A. (IT) | 2011-08-30 | — | — | US | disclosed |
| US-8008514-B2 | Process for preparing 2-methoxycarbonylmethyl-6,6-dimethyl-2-tetrahydropyran carboxylic acid | ERREGIERRE S.P.A. (IT) | 2011-08-30 | — | — | US | disclosed |
| WO-2007009953-A1 | PROCESS FOR PREPARING 2-METHOXYCARBONYLMETHYL-6,6-DIMETHYL-2- TETRAHYDROPYRAN CARBOXYLIC ACID | ERREGIERRE S.P.A. (IT) | 2007-01-25 | — | — | WO | disclosed |
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2006-10-19 | — | — | US | disclosed |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | IVAX International GmbH (CH) | 2005-04-28 | — | — | US | disclosed |
| EP-1064285-B1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | STRAGEN PHARMA SA (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-6831180-B1 | Substituted tertiary carboxylic oxacycloalkane acids, used to prepare anhydro-homo-harringtonic acids by semi-synthesis; hydroxyl function of a cephalotaxane is esterified with a 2-carboxyl-2-alkyl-1-oxacycloalkane claimed intermediate; (indexing from 7169774 added) | STRAGEN PHARMA SA. (CH) | 2004-12-14 | — | — | US | disclosed |
| US-6613900-B2 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | ONCOPHARM CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020045750-A1 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | IVAX International GmbH (CH) | 2002-04-18 | — | — | US | disclosed |
| EP-1064285-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Oncopharm Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999048894-A1 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | ONCOPHARM CORPORATION (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234999-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | ALDH1A1 1136/4885SLC13A5 1151/4885ALOX15 1186/4885 |
| US-20020045750-A1 | Asymetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. | AAAS, AARS1, AADAT | ALDH1A1 804/4885SLC13A5 3516/4885ALOX15 722/4885 |
| US-20050090484-A1 | Cephalotaxane derivatives and their processes of preparation and purification | UGT1A7, CYP8B1, UGT2B7 | ALDH1A1 1136/4885SLC13A5 1151/4885ALOX15 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.